Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

Analysis of Revenues

Microsoft Excel

Revenues as Reported

Eli Lilly & Co., income statement, revenues

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Diabetes and obesity 19,667,600 14,464,800 13,188,100 11,834,400 11,132,100
Oncology 6,658,300 5,666,200 5,741,300 5,319,300 4,614,400
Immunology 3,797,500 3,344,600 3,360,800 2,461,900 1,793,300
Neuroscience 2,878,500 1,546,200 1,898,500 1,831,300 1,722,900
Other human pharmaceutical products 1,122,200 3,519,600 4,129,900 3,092,800 3,056,800
Revenue 34,124,100 28,541,400 28,318,600 24,539,700 22,319,500

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Item Description The company
Revenue Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Eli Lilly & Co. revenue increased from 2021 to 2022 and from 2022 to 2023.